Company intelligence / Profile preview
Neumentum, Inc.
Morristown, New Jersey, United Statesneumentum.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neumentum is developing non-opioid pain management treatments. Their lead product NTM-001 (novel formulation of ketorolac) is in Phase 3 development with top-line results expected in 2024. NTM-006 has completed a positive Phase 2A clinical study in moderate to severe acute pain.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesNSAIDsNovel chemical entities
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Nuance Biotech Co. Ltd (China)
Beyond the preview
Go deeper on Neumentum, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neumentum, Inc..